Bellicum Pharmaceuticals ... (BLCM)
Bellicum Pharmaceuticals Statistics
Share Statistics
Bellicum Pharmaceuticals has 10.41M shares outstanding. The number of shares has increased by 0% in one year.
| Shares Outstanding | 10.41M |
| Shares Change (YoY) | 0% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 6.78M |
| Failed to Deliver (FTD) Shares | 4.45K |
| FTD / Avg. Volume | 15.56% |
Short Selling Information
| Short Interest | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Valuation Ratios
The PE ratio is -0.89 and the forward PE ratio is null. Bellicum Pharmaceuticals's PEG ratio is 0.37.
| PE Ratio | -0.89 |
| Forward PE | n/a |
| PS Ratio | 14.8 |
| Forward PS | null |
| PB Ratio | 11.02 |
| P/FCF Ratio | -0.86 |
| PEG Ratio | 0.37 |
Enterprise Valuation
Bellicum Pharmaceuticals has an Enterprise Value (EV) of 359.34K.
| EV / Sales | 0.24 |
| EV / EBITDA | -0.01 |
| EV / EBIT | -0.01 |
| EV / FCF | -0.01 |
Financial Position
The company has a current ratio of 6.31, with a Debt / Equity ratio of 0.
| Current Ratio | 6.31 |
| Quick Ratio | 6.36 |
| Debt / Equity | 0 |
| Debt / EBITDA | 0 |
| Debt / FCF | 0 |
| Interest Coverage | -586543.48 |
Financial Efficiency
Return on Equity is -1239.35% and Return on Invested Capital is -1339.11%.
| Return on Equity | -1239.35% |
| Return on Assets | -104.83% |
| Return on Invested Capital | -1339.11% |
| Revenue Per Employee | $115.38K |
| Profits Per Employee | $-1.92M |
| Employee Count | 13 |
| Asset Turnover | 0.06 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 2K |
| Effective Tax Rate | -0.01% |
Stock Price Statistics
The stock price has increased by -6.35% in the last 52 weeks. The beta is 1.38, so Bellicum Pharmaceuticals's price volatility has been higher than the market average.
| Beta | 1.38 |
| 52-Week Price Change | -6.35% |
| 50-Day Moving Average | 0.11 |
| 200-Day Moving Average | 0.29 |
| Relative Strength Index (RSI) | 40.84 |
| Average Volume (20 Days) | 28.58K |
Income Statement
In the last 12 months, Bellicum Pharmaceuticals had revenue of 1.5M and earned -24.97M in profits. Earnings per share was -0.81.
| Revenue | 1.5M |
| Gross Profit | 1.5M |
| Operating Income | -26.98M |
| Net Income | -24.97M |
| EBITDA | -26.98M |
| EBIT | -24.97M |
| Earnings Per Share (EPS) | -0.81 |
Balance Sheet
The company has 21.84M in cash and 0 in debt, giving a net cash position of 21.84M.
| Cash & Cash Equivalents | 21.84M |
| Total Debt | 0 |
| Net Cash | 21.84M |
| Retained Earnings | -575.42M |
| Total Assets | 6.85M |
| Working Capital | 4.6M |
Cash Flow
In the last 12 months, operating cash flow was -25.78M and capital expenditures -21K, giving a free cash flow of -25.8M.
| Operating Cash Flow | -25.78M |
| Capital Expenditures | -21K |
| Free Cash Flow | -25.8M |
| FCF Per Share | -0.84 |
Margins
Gross margin is 100%, with operating and profit margins of -1798.73% and -1664.87%.
| Gross Margin | 100% |
| Operating Margin | -1798.73% |
| Pretax Margin | -1664.73% |
| Profit Margin | -1664.87% |
| EBITDA Margin | -1798.73% |
| EBIT Margin | -1798.73% |
| FCF Margin | -1720.27% |
Dividends & Yields
BLCM does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -112.51% |
| FCF Yield | -116.25% |
Analyst Forecast
Currently there are no analyst rating for BLCM.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Stock Splits
The last stock split was on Feb 6, 2020. It was a backward split with a ratio of 1:10.
| Last Split Date | Feb 6, 2020 |
| Split Type | backward |
| Split Ratio | 1:10 |
Scores
| Altman Z-Score | -129.69 |
| Piotroski F-Score | 1 |